Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Electronic Pillbox-enabled Self-administered Therapy Versus Standard DOT for TB Treatment Adherence and Outcomes

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04216420
Recruitment Status : Not yet recruiting
First Posted : January 2, 2020
Last Update Posted : January 13, 2020
Sponsor:
Collaborators:
Addis Ababa University, College of Health Sciences
Emory University
Armauer Hansen Research Institute, Ethiopia
Information provided by (Responsible Party):
Dr. Tsegahun Manyazewal, Addis Ababa University

Tracking Information
First Submitted Date  ICMJE December 27, 2019
First Posted Date  ICMJE January 2, 2020
Last Update Posted Date January 13, 2020
Estimated Study Start Date  ICMJE February 1, 2020
Estimated Primary Completion Date February 1, 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: January 2, 2020)
  • Level of adherence [ Time Frame: Two months ]
    Proportion of patients who missed doses in intervention (pill count) versus DOT (direct observation) arms, confirmed further by urine isoniazid test (IsoScreen test, GFC Diagnostics Ltd, Bicester, England) and a self-report on Morisky Medication Adherence Scale (MMAS-8, an 8-item structured, valid tool to measure self-reported medication adherence).
  • Sputum conversion [ Time Frame: Before and after the two-month intensive phase ]
    Proportion of patients with smear conversion following the intensive phase in intervention versus DOT arms, confirmed further by pre-post intensive phase TB liquid culture and drug susceptibility testing (BD BACTEC MGIT 960 TB system, BD Diagnostics, Maryland, US).
Original Primary Outcome Measures  ICMJE
 (submitted: December 30, 2019)
  • Medication adherence [ Time Frame: Two months ]
    Proportion of patients who missed doses in intervention (pill count) versus DOT (direct observation) arms, confirmed further by urine isoniazid test (IsoScreen test, GFC Diagnostics Ltd, Bicester, England)
  • Treatment outcomes [ Time Frame: Two months ]
    Proportion of patients' with smear conversion following intensive phase in intervention versus DOT arms, confirmed further by TB liquid culture and drug susceptibility testing (BD BACTEC MGIT 960 TB system, BD Diagnostics, Maryland, US)
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: January 3, 2020)
  • Poor treatment outcomes [ Time Frame: Two months ]
    Proportion of patients with poor treatment outcomes (treatment not completed, death, or loss to follow-up) in intervention versus DOT arms.
  • Cost-effectiveness: value of health effects [ Time Frame: Two months ]
    Quality-adjusted life years (QALY) of patients in intervention versus DOT arms under EuroQol's EQ-5D-5L quality of life questionnaire, with discount rates of 3% and a score out of 100, where 100 means the best health a patient imagines.
  • Cost-effectiveness: individual and societal costs of treatment [ Time Frame: Two months ]
    Proportion of individual and societal costs of treatment when management of adherence followed pillbox-enabled SAT versus DOT.
  • Acceptability [ Time Frame: Two months ]
    Proportion of patients in intervention versus DOT arms who perceived satisfaction with their TB treatment when measured on Treatment Satisfaction Questionnaire for Medication scale (TSQM v 1.4, a 14-item valid tool to assess patients' satisfaction with medication across four domains - effectiveness, side effects, convenience, and global satisfaction).
  • Usability [ Time Frame: End of two months ]
    Proportion of patients in the intervention arm who perceived the pillbox-enabled SAT as usable (easy to use, benefiting, adherence motivator, reputable) in an interviewer-administered, close-ended questionnaire.
  • Behavioral determinants [ Time Frame: Two months ]
    Proportion of patients with behavioral factors (use cigarettes, alcohol, chat, cocaine/marijuana) that had adherence problems in the first month of their treatment but improved following additional interventions using Multiphase Optimization Strategy (MOST): i) behavioral intervention, ii) behavioral plus reducing refill schedules to one week (from two weeks), and iii) reassigning to DOT.
  • Social determinants [ Time Frame: Two months ]
    Proportion of patients with social determinants (homeless, unemployed, illiterate) that had adherence problems in the first month of treatment but improved following further interventions using MOST i) behavioral intervention, ii) behavioral plus reducing refill schedules to one week (from two weeks), and iii) reassigning to DOT.
Original Secondary Outcome Measures  ICMJE
 (submitted: December 30, 2019)
  • Usability [ Time Frame: Two months ]
    Proportion of patients in the intervention arm who evaluated the pillbox as usable on System Usability Scale (SUS)
  • Cost-effectiveness [ Time Frame: Two months ]
    Quality-adjusted life year (QALY) in intervention versus DOT arms
  • Acceptability [ Time Frame: Two months ]
    Treatment satisfaction of patients on a Treatment Satisfaction Questionnaire for Medication (TSQM v 1.4) scale in intervention versus DOT arms
  • Behavioral factors [ Time Frame: Two months ]
    Proportion of patients with behavioral factors (use cigarettes, alcohol, chat, cocaine/marijuana) that had adherence problems in the first month of their treatment but improved following additional interventions using Multiphase Optimization Strategy (MOST): i) behavioral intervention, ii) behavioral plus reducing refill schedules to one week (from two weeks), and iii) reassigning to DOT.
  • Social factors [ Time Frame: Two months ]
    Proportion of patients with social factors (homeless, unemployed, illiterate) that had adherence problems in the first month of treatment but improved following further interventions using MOST i) behavioral intervention, ii) behavioral plus reducing refill schedules to one week (from two weeks), and iii) reassigning to DOT.
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title  ICMJE Electronic Pillbox-enabled Self-administered Therapy Versus Standard DOT for TB Treatment Adherence and Outcomes
Official Title  ICMJE Electronic Pillbox-enabled Self-administered Therapy Versus Standard Directly Observed Therapy for Tuberculosis Medication Adherence and Treatment Outcomes in Ethiopia: a Multicenter Randomized Controlled Trial
Brief Summary To address the multifaceted problems associated with tuberculosis (TB) in-person directly observed therapy (DOT), the World Health Organization has recently recommended countries to maximize the use of digital adherence technologies. Sub-Saharan Africa needs to early investigate the effectiveness of such technologies in local contexts and proactively contribute to global decisions around patient-centered TB care. This study aims to evaluate the effectiveness of pillbox-enabled self-administered therapy (SAT) over standard DOT on TB medication adherence and treatment outcomes in Ethiopia. It also aims to assess the usability, cost-effectiveness, and acceptability by patients and healthcare providers of the pillbox-enabled SAT. It is designed as a prospective, multicenter, open-label, randomized, controlled, superiority, mixed-methods trial, supplemented with multiphase optimization strategy (MOST) for interventions on behavioral and social determinants of adherence.
Detailed Description Not Provided
Study Type  ICMJE Interventional
Study Phase  ICMJE Not Applicable
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description:
Prospective, multicenter, open-label, randomized, controlled, superiority, mixed-methods trial, supplemented with Multiphase Optimization Strategy (MOST) for interventions on behavioral and social determinants of adherence.
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Tuberculosis
Intervention  ICMJE Device: Electronic pillbox-enabled SAT
It is a device manufactured by Wisepill Technologies, South Africa. Every time a pill dispenser is opened, the evriMED500 stores the date and time of the opening. Adherence data and reports can be viewed on the Wisepill Cloud Server and on the mobile-friendly browser application.
Other Name: evriMed500 medication monitoring and reminder system
Study Arms  ICMJE
  • Experimental: Electronic pillbox-enabled self-administered therapy (SAT)
    TB patients in the experimental arm will be dispensed with TB medication supply (HRZE fixed-dose combination therapy) for every 15 days in medication event reminder monitor (MERM) pillbox device (evriMed500 digital medication monitoring and reminder device manufactured by Wisepill Technologies, South Africa) to self-administer throughout the intensive phase
    Intervention: Device: Electronic pillbox-enabled SAT
  • No Intervention: Standard directly observed therapy (DOT)
    TB patients in the standard DOT arm will visit the healthcare facility each business day in the intensive (2 months) phase to swallow their daily dose of HRZE with direct observation of the healthcare provider per the standard currently practicing DOT procedure.
Publications * Manyazewal T, Woldeamanuel Y, Holland DP, Fekadu A, Blumberg HM, Marconi VC. Electronic pillbox-enabled self-administered therapy versus standard directly observed therapy for tuberculosis medication adherence and treatment outcomes in Ethiopia (SELFTB): protocol for a multicenter randomized controlled trial. Trials. 2020 May 5;21(1):383. doi: 10.1186/s13063-020-04324-z.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Not yet recruiting
Estimated Enrollment  ICMJE
 (submitted: December 30, 2019)
144
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE July 31, 2021
Estimated Primary Completion Date February 1, 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Patients with new or previously treated bacteriologically confirmed drug-sensitive pulmonary TB
  • Eligible to start the standard 6-month first-line anti-TB medication
  • Outpatient
  • Men or women age 18 to 75 years
  • Able and willing to provide informed consent

Exclusion Criteria:

  • Patients with known drug-resistant TB
  • Any condition that causes cognitive impairment such as severe acute illness or injury, developmental retardation, or severe psychiatric illness and thus precludes informed consent or safely participating in the study procedures
  • Inpatients
  • Expected to move away from the study site before the final study follow up at month two
  • Concurrent extrapulmonary TB
  • Contraindicated medications
  • Active liver disease that requires a TB regimen other than HREZ
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Tsegahun Manyazewal, PhD 118961396 ext +251 tsegahunm@gmail.com
Contact: Yimtubezinash Woldeamanuel, MD, PhD 118961396 ext +251 yimtubezenash.wamanuel@aau.edu.et
Listed Location Countries  ICMJE Ethiopia
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT04216420
Other Study ID Numbers  ICMJE 077/19/CDT
D43TW009127 ( U.S. NIH Grant/Contract )
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE
Plan to Share IPD: Undecided
Responsible Party Dr. Tsegahun Manyazewal, Addis Ababa University
Study Sponsor  ICMJE Addis Ababa University
Collaborators  ICMJE
  • Addis Ababa University, College of Health Sciences
  • Emory University
  • Armauer Hansen Research Institute, Ethiopia
Investigators  ICMJE Not Provided
PRS Account Addis Ababa University
Verification Date January 2020

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP